To report 4-year outcomes of the randomized controlled trial of water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
Total 188 subjects; 135 men ≥50 years old, IPSS ≥13, maximum flow rate (Qmax) ≤15 ml/s and prostate volume 30 to 80 cc treated with Rezūm® System thermal therapy were followed 4 years; subset of 53 men who requalified for cross-over from control to active treatment were followed 3 years.
LUTS were significantly improved within ≤3 months after thermal therapy and remained consistently durable (IPSS 46%, QOL 42%, Qmax 50%, BPH Impact Index 51%) throughout 4 years (P < .0001); outcomes were similarly sustained in crossover subjects at 3 years. Surgical retreatment rate was 4.4% over 4 years. No disturbances in sexual dysfunction were reported.
The minimally invasive thermal therapy provides effective symptom relief and improved QOL that remains durable for over 4 years. It is applicable to all prostate zones with procedures performed under local anesthesia in an office setting.
Urology. 2019 Jan 21 [Epub ahead of print]
Kevin T McVary, Tyson Rogers, Claus G Roehrborn
Department of Urology, Loyola University Medical Center, Maywood, IL. Electronic address: ., NAMSA, Minneapolis, MN., Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.